Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

By N. Senzer, H. Kaufman, T. Amatruda, M. Nemunaitis, T. Reid, G. Daniels, R. Gonzalez, J. Glaspy, E. Whitman, Kevin J. Harrington and 5 more. Journal of Clinical Oncology, 2009

623 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/17134187e1f968f75bab96ef3347c94f22a3386d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. K. Palucka
2. Jacques Banchereau
3. Sylvia M. Lee
4. J. Wolchok
5. K. Margolin

In Oncology

1. K. Palucka
2. Jacques Banchereau
3. Sylvia M. Lee
4. J. Wolchok
5. K. Margolin

Citations in the corpus

• The future of cancer immunotherapy: microenvironment-targeting combinations (2020, background): “T-VEC has demonstrated robust T cell responses at the injected site and distant tumor sites.(59,60) Combination trials with oncolytic viruses represent an active frontier of immuno-oncology.”
• Cytokines in Cancer Immunotherapy (2011, background): “patients with unresectable Stage IIIc or IV melanoma [186].”
• Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “A phase II study of GM-CSF-oncolytic herpes virus in individuals with stage IIIc and stage IV melanoma indicated durable regression in both injected and noninjected lesions, suggesting a systemic effect (Senzer et al., 2009).”